CREO Creo Medical Group Plc

TIDMCREO

RNS Number : 2975L

Creo Medical Group PLC

05 September 2023

Creo Medical Group plc

("Creo" the "Company" or the "Group")

Notice of Interim Results

Investor Presentation

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, will announce its interim results for the six months ended 30 June 2023 on Tuesday, 12 September 2023.

Investor Presentation

Craig Gulliford, Chief Executive Officer, and Richard Rees, Chief Financial Officer, will provide a live presentation covering the interim results via the Investor Meet Company platform on Tuesday, 12 September 2023 at 17:00 BST.

The presentation is open to all existing/potential shareholders and analysts. Questions can be submitted at any time during the live presentation.

Investors can sign up to Investor Meet Company at no additional cost and register in advance to meet Creo Medical Group plc via: https://www.investormeetcompany.com/creo-medical-group-plc/register-investor

Investors who already follow Creo Medical Group plc on the Investor Meet Company platform will automatically be invited.

-Ends-

Enquiries:

 
 Creo Medical Group plc                                                 www.creomedical.com 
 Richard Rees (CFO)                                                     +44 (0)1291 606 005 
 
 Cenkos Securities plc                                                  +44 (0)20 7397 8900 
 Stephen Keys / Camilla Hume (NOMAD) 
 Michael Johnson / Russell Kerr (Joint 
  Broker) 
 
 Numis Securities Limited (Joint 
  Broker)                                                               +44 (0)20 7260 1000 
 Freddie Barnfield / Duncan Monteith 
  / Euan Brown 
 
 Walbrook PR Ltd                          Tel: + 44 ( 0)20 7933 8780 or creo@walbrookpr.com 
 Paul McManus / Sam Allen / Phillip                  Mob: +44 (0)7980 541 893 / +44 (0)7502 
  Marriage                                                    558 258 / +44 (0)7867 984 082 
 

About Creo Medical

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORFZLFBXKLFBBZ

(END) Dow Jones Newswires

September 05, 2023 02:00 ET (06:00 GMT)

Creo Medical (LSE:CREO)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Creo Medical (LSE:CREO)
Gráfica de Acción Histórica
De May 2023 a May 2024